Mercachem logo voor websites


Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.


Bionetix web

 

Bionetix, a biotech company developing novel oncology drugs; ProQinase, an oncology-focused contract research organization (CRO) recently acquired by Reaction Biology Corporation (Malvern/PA, USA); and MercachemSyncom, a chemistry CRO specializing in medicinal chemistry and comprehensive medicinal chemistry (CMC), today announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification (TI) up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML). The goal of the three-party team is to advance the project to the clinical phase by 2023. The total investment sum is “significant, of multimillion Euros”, but details are not being disclosed.

Full press release   

Contact us